Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

  • In development
  • GID-TA11819
  • Expected publication date: TBC

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators